Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback